Joseph Martel, MD
Ophthalmology · Rancho Cordova, CANPI 1063439776
Payments from drug & device makers
Across 636 payments — averaging $3087.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$504K
- Novartis$440K
- Oyster Point Pharma, Inc.$365K
- Bausch Health US, LLC$223K
- Kala Pharmaceuticals, Inc.$200K
- Glaukos Corporation$113K
- plus $120K from 25 others
Across 33 payments — averaging $9232.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$165K
- Argenx US, Inc.$102K
- Sun Pharmaceutical Industries Inc.$34K
- Glaukos Corporation$4K
What the payments were for
- Consulting fees$10,40064%
- Travel & lodging$2101%
- Food & beverage$5,68935%
- Entertainment$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 131 | $503,518 |
| Novartis | 18 | $439,956 |
| Oyster Point Pharma, Inc. | 29 | $364,932 |
| Bausch Health US, LLC | 24 | $222,609 |
| Kala Pharmaceuticals, Inc. | 22 | $199,831 |
| Glaukos Corporation | 40 | $113,212 |
| Dompe US, Inc. | 6 | $78,653 |
| Bausch & Lomb Americas Inc. | 52 | $18,882 |
| Argenx US, Inc. | 140 | $13,437 |
| Shire North American Group Inc | 1 | $5,690 |
| Alcon | 33 | $711 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 64 | $660 |
| Eyevance Pharmaceuticals LLC | 14 | $238 |
| Amgen(2 entities) | 11 | $237 |
| Aerie Pharmaceuticals, Inc. | 14 | $229 |
| Biotissue Holdings Inc. | 11 | $202 |
| Sight Sciences, Inc. | 3 | $111 |
| Sandoz | 1 | $105 |
| Sun Pharmaceutical Industries Inc. | 4 | $92 |
| Genentech USA, Inc. | 3 | $69 |
| Harrow Eye, LLC | 2 | $65 |
| Mallinckrodt Hospital Products Inc. | 3 | $64 |
| Astellas Pharma US Inc | 2 | $38 |
| Apellis Pharmaceuticals, Inc. | 1 | $31 |
| Rayner Intraocular Lenses Limited | 1 | $30 |
| Thea Pharma Inc. | 1 | $25 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Optos, Inc. | 1 | $23 |
| Carl Zeiss Meditec USA, Inc. | 1 | $17 |
| Tarsus Pharmaceuticals, Inc. | 1 | $16 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,963,720 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 162 | $79,884 |
| VyzultaLatanoprostene Bunod | 103 | $39,946 |
| RestasisCyclosporine | 24 | $33,884 |
| Prednisolone Acetate | 698 | $25,474 |
| RocklatanNetarsudil Mesylat/Latanoprost | 66 | $25,427 |
| Alphagan PBrimonidine Tartrate | 62 | $23,161 |
| ProlensaBromfenac Sodium | 68 | $23,003 |
| XiidraLifitegrast | 20 | $22,498 |
| Cyclosporine | 36 | $21,327 |
| Restasis MultidoseCyclosporine | 21 | $21,234 |
| Bromfenac Sodium | 88 | $16,531 |
| CombiganBrimonidine Tartrate/Timolol | 36 | $15,717 |
| Timolol Maleate | 202 | $14,291 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 68 | $14,210 |
| MoxifloxacinMoxifloxacin Hcl | 425 | $9,889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Restasis Multidose, Combigan | $503,518 | $173,880305 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $18,882 | $62,444123 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $229 | $25,42766 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $660 | $23,00368 claims |
| AlconSimbrinza | $711 | $14,21068 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Rancho Cordova
- Liliya GolasRancho Cordova$1.7M
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.